A Step Closer to Predicting Progression After Bacillus Calmette-Guérin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer

Madhuri Koti; D Robert Siemens

doi:10.1016/j.eururo.2023.06.017

A Step Closer to Predicting Progression After Bacillus Calmette-Guérin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer

Eur Urol. 2023 Nov;84(5):447-448. doi: 10.1016/j.eururo.2023.06.017. Epub 2023 Jul 1.

Authors

Madhuri Koti¹, D Robert Siemens²

Affiliations

¹ Department of Biomedical and Molecular Sciences, Department of Urology, Cancer Research Institute, Queen's University, Kingston, ON, Canada. Electronic address: kotim@queensu.ca.
² Department of Biomedical and Molecular Sciences, Department of Urology, Cancer Research Institute, Queen's University, Kingston, ON, Canada.

PMID: 37400353
DOI: 10.1016/j.eururo.2023.06.017

Abstract

Treatment-naïve tumors from patients who then experience recurrence or progression after bacillus Calmette-Guérin (BCG) therapy exhibit elevated expression of genes associated with basal differentiation and immune suppression. Three tumor molecular subtypes have been associates with distinct clinical outcomes and will allow early identification of patients unlikely to respond to BCG immunotherapy.

Trial registration: ClinicalTrials.gov NCT05538663.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adjuvants, Immunologic / therapeutic use
Administration, Intravesical
BCG Vaccine / therapeutic use
Humans
Immunotherapy / adverse effects
Neoplasm Invasiveness
Neoplasm Recurrence, Local / drug therapy
Non-Muscle Invasive Bladder Neoplasms*
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / genetics

Substances

BCG Vaccine
Adjuvants, Immunologic

Associated data

ClinicalTrials.gov/NCT05538663

Grants and funding

CIHR/Canada